Does Rallies show Form 4 insider transactions for IRON?

Yes. Rallies tracks IRON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IRON research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IRON. It does not provide personalized investment advice.

IRON (Disc Medicine, Inc. Common Stock) Stock Analysis - Insider Trades

Disc Medicine, Inc. Common Stock (IRON) is a publicly traded Healthcare sector company. As of May 20, 2026, IRON trades at $66.94 with a market cap of $2.55B and a P/E ratio of -11.02. IRON moved +4.67% today. Year to date, IRON is -14.75%; over the trailing twelve months it is +33.85%. Its 52-week range spans $30.82 to $99.50. Analyst consensus is strong buy with an average price target of $98.22. Rallies surfaces IRON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IRON stock inside the company?

Recent IRON insider activity includes Franchi Jean M. sold 6.26K, Savage William Jacob sold 3.53K, Savage William Jacob sold 2.20K, Franchi Jean M. sold 400, and Savage William Jacob sold 4.39K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IRON Key Metrics

Key financial metrics for IRON
Metric	Value
Price	$66.94
Market Cap	$2.55B
P/E Ratio	-11.02
EPS	$-6.01
Dividend Yield	0.00%
52-Week High	$99.50
52-Week Low	$30.82
Volume	381.69K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-212.18M
Gross Margin	0.00%

Recent IRON Insider Trades

Franchi Jean M. sold 6.26K (~$433.23K) on Apr 14, 2026.
Savage William Jacob sold 3.53K (~$233.47K) on Apr 13, 2026.
Savage William Jacob sold 2.20K (~$146.98K) on Apr 13, 2026.
Franchi Jean M. sold 400 (~$27.60K) on Apr 13, 2026.
Savage William Jacob sold 4.39K (~$287.77K) on Mar 2, 2026.

Latest IRON News

Disc Medicine Completes 183-Patient Phase 3 Enrollment, Holds $730M Cash Runway — May 5, 2026
Disc Medicine Expands Phase 3 APOLLO Trial to 183 Patients, Data Due Q4 2026 — Mar 26, 2026
Disc Medicine Posts $791 M Cash, FDA CRL for Bitopertin, Q4 2026 Readout — Feb 26, 2026
Disc Medicine Shares Drop 22% After FDA CRL on Bitopertin Approval — Feb 17, 2026
Disc Medicine Receives FDA CRL, Eyes Q4 2026 APOLLO Phase 3 Topline — Feb 13, 2026

IRON Analyst Consensus

10 analysts cover IRON: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $98.22.

Common questions about IRON

Who is trading IRON stock inside the company?: Recent IRON insider activity includes Franchi Jean M. sold 6.26K, Savage William Jacob sold 3.53K, Savage William Jacob sold 2.20K, Franchi Jean M. sold 400, and Savage William Jacob sold 4.39K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IRON?: Yes. Rallies tracks IRON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IRON research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IRON. It does not provide personalized investment advice.